3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)

✍ Scribed by J. Baselga; J.G.M. Segalla; H. Roché; A. del Giglio; E.M. Ciruelos; S. Cabral Filho; P. Gomez; A. Lluch; A. Llombart; F. Costa

• Book ID: 119600773
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 68 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(09)72031-2